RT Journal Article
SR Electronic
T1 Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.28.21255834
DO 10.1101/2021.04.28.21255834
A1 Sergio Fragoso-Saavedra
A1 Isaac Núñez
A1 Belem M. Audelo-Cruz
A1 Sarahi Arias-Martínez
A1 Daniel Manzur-Sandoval
A1 Alejandro Quintero-Villegas
A1 H. Benjamín García-González
A1 Sergio L. Carbajal-Morelos
A1 Sergio Ponce de León-Rosales
A1 José Gotés-Palazuelos
A1 José A. Maza-Larrea
A1 Yanink Caro-Vega
A1 Isabella Batina
A1 León Islas-Weinstein
A1 David A. Iruegas-Nunez
A1 Juan J. Calva
A1 Pablo F. Belaunzarán-Zamudio
A1 Juan Sierra-Madero
A1 José C. Crispín
A1 Sergio I. Valdés-Ferrer
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.28.21255834.abstract
AB Background Hospitalized patients with severe COVID-19 have an increased risk of developing severe systemic inflammatory response, pulmonary damage, and acute respiratory distress syndrome (ARDS), resulting in end-organ damage and death. Acetylcholine modulates the acute inflammatory response through a neuro-immune mechanism known as the inflammatory reflex. Pyridostigmine, an acetylcholine-esterase inhibitor, increases the half-life of endogenous ACh, chemically stimulating the inflammatory reflex. This trial aimed to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19.Methods We performed a parallel-group, multicenter, double-blinded, placebo-controlled, randomized clinical trial to evaluate if add-on pyridostigmine to standard treatment reduced the composite outcome of initiation of IMV and 28-day all-cause mortality among hospitalized patients with severe COVID-19.Results 188 participants were randomly assigned to placebo (n=94) or pyridostigmine (n=94). The composite outcome occurred in 22 (23.4%) vs. 11 (11.7%) participants, respectively (hazard ratio 0.46, 95% confidence interval 0.22-0.96, p=0.03). Most of the adverse events were mild to moderate, with no serious adverse events related to pyridostigmine; discontinuation of the study drugs was similar in both groups.Conclusions We provide evidence indicating that the addition of pyridostigmine to standard treatment resulted in a clinically significant reduction in the composite outcome (IMV/death) among patients hospitalized for severe COVID-19. (Funded by Consejo Nacional de Ciencia y Tecnología, México; ClinicalTrials.gov number: NCT04343963).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04343963Clinical Protocols https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05485-7 Funding StatementFunded by Consejo Nacional de Ciencia y Tecnología, México (COVID-19 Fund [F0005-2020-01]; grant 311790), to SIV-F].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comité de Investigación en Humanos y Comité de Ética en Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data will be made available upon request to the corresponding author